Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(RWQWRWQWR)2K-Ahx-RRWQWR
- Development stage
- Preclinical
- Lead developer
- Universidad Nacional de Colombia
- Modality
- Peptides
01
Overview
(RWQWRWQWR)2K-Ahx-RRWQWR is a synthetic hybrid dimeric-monomeric peptide designed for anticancer activity, specifically targeting cervical cancer. Developed by researchers at the Universidad Nacional de Colombia and Pontificia Universidad Javeriana, the molecule's design is based on the palindromic sequence RWQWRWQWR, derived from bovine lactoferricin (LfcinB), which is known for its anticancer properties. This specific variant (Code 18) features a dimeric core of the palindromic sequence branched on a lysine residue, linked via a 6-aminohexanoic acid (Ahx) spacer to the hexapeptide RRWQWR. Its mechanism of action involves electrostatic interactions between its cationic arginine residues and the negatively charged components of cancer cell surfaces, followed by membrane disruption or internalization. In vitro studies demonstrate significant cytotoxic activity against HeLa and Ca Ski cervical cancer cell lines, with a rapid effect observed within two hours.
- Other names
- hybrid dimeric-monomeric peptide 18
Beyond the preview
Go deeper on (RWQWRWQWR)2K-Ahx-RRWQWR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (RWQWRWQWR)2K-Ahx-RRWQWR.